Figure 2
Figure 2. Time to first positive CMV hybrid capture assay. (A) Kaplan-Meier plot of time to first positive CMV DNA hybrid capture assay by CMV donor/recipient serostatus among HSC transplant recipients that did not receive sirolimus-tacrolimus prophylaxis. (B) Kaplan-Meier plot of time to first positive CMV DNA hybrid capture assay by CMV donor/recipient serostatus among HSC transplant recipients that received sirolimus-tacrolimus prophylaxis. (C) Kaplan-Meier plot of time to first positive CMV DNA hybrid capture assay stratified by sirolimus-tacrolimus GVHD prophylaxis and incident grades II-IV GVHD.

Time to first positive CMV hybrid capture assay. (A) Kaplan-Meier plot of time to first positive CMV DNA hybrid capture assay by CMV donor/recipient serostatus among HSC transplant recipients that did not receive sirolimus-tacrolimus prophylaxis. (B) Kaplan-Meier plot of time to first positive CMV DNA hybrid capture assay by CMV donor/recipient serostatus among HSC transplant recipients that received sirolimus-tacrolimus prophylaxis. (C) Kaplan-Meier plot of time to first positive CMV DNA hybrid capture assay stratified by sirolimus-tacrolimus GVHD prophylaxis and incident grades II-IV GVHD.

Close Modal

or Create an Account

Close Modal
Close Modal